Menu
Close
Home
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Latest Development
Company News
Investor Relations
Information Disclosure
Presentations
Corporate Governance
Investor Calendar
IR Contact
Join Us
Contact Us
Global
CN
TC
Home
CN
TC
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Scientific News
Company News
Investor Relations
Information Disclosure
Corporate Governance
Investor Calendar
Presentation Materials
Stock Information
Analyst Coverage
IR Contact
Email Subscription Center
Join Us
Contact Us
>
×
Company News
Home
Company News
News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1395
Previous article：
ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：
ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-07-27
ImmuneOnco Successfully Convenes Phase II Investigator Meeting for IMC-002 (IMM0306) in Active Systemic Lupus Erythematosus (SLE)
More
2026-07-21
IMM2510S，the Subcutaneous Formulation of IMM2510 Completes First Patient Dosing in Phase I Clinical Study, Ushering in a New Era of Convenient Dual-Target Therapy
More
2026-07-16
ImmuneOnco Completes planned Enrollment of 173 Patients in Phase III Registrational Trial of Timdarpacept (IMM01) for CMML
More
For more information
Please follow the official wechat public account
2023-03-23
1395
